•  Treatment of newly diagnosed glioblastoma multiforme.
• Treatment of refractory anaplastic astrocytoma

Temobenz 20mg Capsule acts by inhibiting the production of genetic material (DNA and RNA) of the cancer cells, which results in preventing their cell growth and multiplication, thereby preventing cancer spread to other parts of the body.

Inform your doctor about any medicines you take or have taken before the treatment.

• Keep Temobenz 20mg Capsule out of sight and reach of children.
• Store protected from light and moisture.
• Do not store above 25°C.

Use as directed by your physician. Your physician will prescribe an adequate dose according to your height and weight. Swallow the capsule whole with a glass of water, on an empty stomach. Do not open, crush or chew the capsule and avoid contact of the open capsules with your skin.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.

Serious:

• Secondary cancer like myelodysplastic syndrome and myeloid leukemia.
• Severe Allergic reactions
• Inflammation and fluid buildup in lungs
• Blood clot in lungs or legs
• Liver toxicity
• Convulsions
• Fever and chills
• Severe headache
• Uncontrolled bleeding

Common:

• Hair loss
• Rashes
• Tiredness
• Nausea, vomiting and diarrhea
• Constipation
• High blood sugar levels
• Dizziness, impaired sensation, tingling sensation, abnormal taste
• Vision and Hearing problem
• Frequent urination
• Muscle damage, pain in muscles and joints
• Weight changes
• Infections and wounds
• Amnesia
• Abnormal blood cell counts
• Loss of appetite
• Sleep problems
• Memory loss
• Difficulty concentrating, changes in mental status and alertness
• Coordination problems

• Effective birth control is mandatory for both men and women during Temobenz 20mg Capsule treatment.

• Women of reproductive potential must use contraception during treatment and for 6 months after completing therapy.

• Men should avoid fathering children and use reliable contraception during treatment and for 3 months after it ends.

• Routine blood tests may be recommended to monitor:

  • Electrolyte levels

  • Blood cell count

  • Liver function

1. Sun Pharmaceutical Industries, Electronic Medicines Compendium (EMC) [Revised on Feb 2022] [Accessed on 21 Nov 2022] https://www.medicines.org.uk/emc/files/pil.5318.pdf 

2. Pfizer, US Food and Drug Administration, [Revised on Sep 2015] [Accessed on 21 Nov 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf 

3. Neha Singh et al., Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review, Cancer Drug Resist; Published on Mar 2021; Accessed on 21/09/2022; https://cdrjournal.com/article/view/3779 

4. Zerong Tian et al., Glioblastoma and Anaplastic Astrocytoma: Differentiation Using MRI Texture Analysis, Front. Oncol., Published on Sep 2019; Accessed on 21/09/2022;  https://www.frontiersin.org/articles/10.3389/fonc.2019.00876/full